![](https://endpts.com/wp-content/uploads/2020/11/Genentech-social-shutterstock-Michael-Vi-scaled.jpg)
Genentech ends SHP2 deal with Relay Therapeutics after other pharma exits
Roche’s Genentech is scrapping a collaboration and license agreement with Relay Therapeutics surrounding the biotech’s clinical-stage oral SHP2 inhibitor. It’s the latest pharmaceutical company to … Sign up to read this article for …